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ABSTRACT
Introduction: Aggressive variants of papillary
thyroid cancer (PTC) have been described with
increasing frequency. These variants include
diffuse sclerosing variant, tall cell variant,
columnar cell variant, solid variant, and hob-
nail variant.
Methods: We have performed a review of the
more aggressive variants of PTC with respect to
main characteristics, histological and molecular
features, and the consequences that the
knowledge of these variants should have in the
treatment of the patients.
Results: At the present time, we do not know
the prognostic value of these aggressive PTC
variants. The extent of the surgical treatment
and adjuvant therapy necessary should be
decided on the basis of the extent of the tumor
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at presentation and the opinion of experienced
clinicians.
Conclusion: These aggressive variants should
be known by clinicians, to avoid underdiagno-
sis, and treated according to the latest recom-
mendations in the literature.
Keywords: Aggressive variants papillary
thyroid cancer; Columnar cell variant; Diffuse
sclerosis variant; Hobnail variant; Solid variant;
Tall cell variant
Key Summary Points
There are a small group of tumors among
papillary thyroid cancers with a more
aggressive behavior, higher rates of
recurrence, and metastasis.
Achieving a correct histological diagnosis
of these variants is essential for the
prognosis of patients.
Knowing the clinical characteristics of
these tumors can help us suspect their
presence, given the different clinical signs
of aggressiveness they show.
After the diagnosis it is important to carry
out a more aggressive treatment than in
the classic variants.
Each patient must be evaluated
individually in order to provide the
appropriate surgical treatment as well as a
complementary treatment trying to
improve their prognosis.
INTRODUCTION
Papillary thyroid carcinoma (PTC) is the most
common endocrine malignancy [1]. It repre-
sents approximately 85% of all follicular
derived well-differentiated thyroid cancers.
With a 10-year survival of approximately 93%,
it is considered an indolent tumor [2]. Despite
the fact that the majority of PTCs are well dif-
ferentiated with a low rate of local invasion,
recurrences, or metastases (regional or distant),
there are a small group of tumors which show
heterogeneity with more aggressive variants,
with distinct clinical, pathological, and
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molecular features. These pathological subtypes
are considered in the latest American Thyroid
Association (ATA) guidelines as conferring an
intermediate risk of recurrence [3]. Among the
most aggressive variants of PTC are the diffuse
sclerosing variant (DSV), tall cell variant (TCV),
columnar cell variant (CCV), solid variant (SV),
and hobnail variant (HV). These variants have
been associated with higher rates of recurrence
and metastasis, as well as in some cases absence
of avidity to radioiodine (RAI) therapy and may
have lower survival rate [4]. Given the lack of
knowledge of the natural history of these more
aggressive variants, the treatment of these
patients is often inadequate or suboptimal. The
aim of this review is to describe the aggressive
variants of PTC, emphasizing their differential
histological and molecular characteristics
(Table 1), their clinical manifestations, biologi-
cal behavior, and the implications these vari-
ants have on selection of treatment and
prognosis.
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
AGGRESSIVE VARIANTS OF PTC
Diffuse Sclerosing Variant
Main Features
DSV accounts for almost 6% of all PTCs [5]. It
was reported as a variant of PTC by Vickery et al.
in 1985 [6]. This lesion often presents as a dif-
fuse enlargement of the thyroid gland usually
without forming a dominant nodular lesion [1].
When compared with classic PTC, DSV has
unique clinical features, including a higher
prevalence of underlying Hashimoto’s thy-
roiditis, higher female-to-male ratio, and
younger age [7]. In the report by Pillai et al. [8],
after reviewing 25 studies with 641 patients
affected by a DSV, they found that it is most
often seen in the third decade of life with a
mean age at presentation of 30 years (median
28, range 6–78 years). Eighty-one percent were
female and 19% were male, with a female-to-
male ratio of 4.3:1. On the other hand, there are
studies in which the age of onset is higher,
around 40 years or older [9–11].
In the study by Fridman et al. [12] in 2012,
this variant of PTC was most often seen after
exposure to high levels of radiation (such as the
Chernobyl accident). This was also reported in
the study by Nikiforov and Gnepp [13] where
10% of pediatric PTCs after that accident were
DSV. DSV appears to be more aggressive than
classic PTC and shows at presentation a high
frequency of cervical and pulmonary metastases
[10, 14]. Despite this aggressive behavior, the
overall disease-specific survival rate was similar
to the classic type. This was demonstrated in the
study by Lam and Lo [9] after a median follow-
up period of 10.7 years. The overall disease-
specific survival rate was 93%, similar to classic
PTC. Furthermore, in the aforementioned study
by Pillai et al. [8] cancer recurrence and cancer-
related mortality were reported in 14% and 3%,
respectively, whereas distant metastases were
noted in approximately 5% of the cases. In
2012, Kazaure et al. [11] published a retrospec-
tive review of the Surveillance, Epidemiology,
and End Results (SEER) database from 1988 to
2008 including 261 patients with DSV, 573 with
TCV, and 42,904 with PTC. They reported a
20-year increase in the incidence of classic PTC
of 60.8%, while DSV and TCV incidence
increased by 126% and 158%, respectively.
These aggressive variants were associated with
higher rates of extrathyroid extension, multi-
focality, and nodal (DSV 72.2% vs. 66.8% TCV
vs. 56.3% PTC, P\0.001) and distant metas-
tases (TCV 11.1% vs. 7.3% DSV vs. 4.3% PTC,
P\ 0.001) compared to classic PTC. In this
study, survival was decreased in both aggressive
variants, but the difference was greater for TCV
(5-year overall survival 87.5% DSV, 80.6% TCV
vs. 93.5% PTC, P\ 0.001). Thyroid surgery and
RAI therapy were independently associated with
improved overall survival. In a systematic
review of DSV, Vuong et al. [15] identified 732
cases of DSV in 16 articles. They found that DSV
manifested more aggressive clinicopathological
behavior than classic PTC such as higher rate of
vascular invasion (odds ratio [OR] 5.33; 95% CI
3.08–9.23), extrathyroid extension (OR 2.96;
95% CI 2.04–4.30), lymph node metastasis (OR
5.40; 95% CI 2.82–10.35), and distant
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metastasis (OR 3.61; 95% CI 1.89–6.88). DSVs
were more likely to relapse (OR 2.83; 95% CI
1.59–5.05) and were associated with a worse
overall survival (hazard ratio [HR] 1.89; 95% CI
1.36–2.62).
Diagnosis
Histological Features
The main histological characteristic is a diffuse
involvement of one or both thyroid lobes with
Table 1 Main histological characteristics of the aggressive variants of PTC
Variant Clinical features Histology Molecular
DSV Diffuse enlargement
ETE
Associated Hashimoto’s thyroiditis
2nd–3rd decade of life
Diffuse involvement of one or both lobes
Micropapillary tumor clusters in cleft-like spaces
consistent with lymphatics
Squamous metaplasia
Numerous psammoma bodies
Extensive lymphocytic infiltration of tumor
Marked tumor fibrosis
RET/PTC1
RET/PTC3
BRAFV600E
mutations
(50–61%)
TCV Large tumor size
ETE
5th–6th decade of life
C 30% tall cells (height twice their width) with
oncocytic cytoplasm
Elongated follicles
BRAF mutations
(80–100%)
CCV Infiltrative form with extrathyroid
extension: rapid growth rate
Local invasion
Early lymph node metastasis
High rate of recurrences
5th–6th decade of life
Encapsulated form minimally invasive:
high cure rate
Columnar cells with pseudostratified nuclei and
no eosinophilic cytoplasm
Hypercellular neoplasm with thin papillae and
glandular structures
Nuclear features of papillary carcinoma not as
well developed as classic PTC
Occasional subnuclear vacuolization or even
clear cytoplasm
BRAFV600E (33%)
SV 5th decade of life
Large tumor size
ETE
Higher risk of metastasis
Solid nested growth pattern
Well-developed nuclear features of PTC
Lack of tumor necrosis
Absence of marked mitotic activity
RET/PTC3
BRAF mutation
HV 6th decade of life
ETE
Lymph node metastasis
C 30% of hobnail cells
Micropapillary growth patterns
High nuclear/cytoplasmic ratio
BRAF mutations
(25%)
TP53 mutations
(55%)
NOTCH1
mutations (5%)
DSV diffuse sclerosing variant, TCV tall cell variant, CCV columnar cell variant, SV solid variant, HV hobnail variant, ETE
extrathyroidal extension
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dense sclerosis, patchy to dense lymphocytic
infiltrates, abundant psammoma bodies, exten-
sive squamous metaplasia, and extensive lym-
phovascular invasion [1] (Fig. 1a, b). Takagi et al.
[16] described the characteristics of DSV in fine
needle aspiration (FNA) cytology as follows: solid
cell balls and/or hollow balls containing lym-
phocytes; hobnail cells; septate cytoplasmic vac-
uoles; large unilocular vacuoles; squamous
differentiation; abundant psammoma bodies;
lymphocytic background; and the absence or
relative lack of characteristic nuclear features of
PTC. They reported that 17 out of 20 patients
with DSV had Hashimoto’s thyroiditis. The
coexistence with Hashimoto’s thyroiditis can
make diagnosis of this tumor by FNA difficult [8].
It is important not to confuse the squamous
metaplasia found in DSV with anaplastic carci-
noma with squamous features. The lack of
nuclear pleomorphism in the squamous nests and
of course the young age of the patient should
guide the pathologist toward a diagnosis of DSV.
Some authors such as Koo et al. [17] have
studied different immunohistochemical char-
acteristics that may define DSV. They found
that immunohistochemical staining for p63 was
positive in 28.6% of cases with DSV in the
squamous metaplasia, p53 was noted in 42.9%
in the solid component, and Galectin-3 was not
expressed in 16.3% of the cases. EMA was posi-
tive in 40.8%.
Molecular Features
The molecular profile of DSV is variable; the
common genetic alterations are rearranged
during transfection/papillary thyroid carcinoma
(RET/PTC) rearrangements (RET/PTC1[RET/
PTC3) and BRAFV600E mutations. RET/PTC3
alterations are seen in patients who present at
an advanced disease stage and who have a poor
clinical outcome [18, 19]. In 2016, Joung et al.
[20] investigated the genetic alterations of DSV.
They found RET/PTC rearrangements as the
major molecular alteration which was associ-
ated with an advanced stage at diagnosis and a
poor clinical outcome. RET/PTC rearrangements
are commonly seen in pediatric PTCs, so the
high incidence of this molecular finding in DSV
might be a matter of age of the patients, the
same as the overall good survival despite the
aggressive clinical presentation. BRAF mutation
has also been observed in DSV, but at lower
frequency than in PTC [21, 22]. However, the
reported rates of BRAF mutation vary signifi-
cantly between studies. Lee et al. [23] reported
BRAF mutation in 50% of DSV cases, while
classic PTC showed a 62% positivity rate. Lim
et al. [24] confirmed these results although with
somewhat different percentages (DSV 61%, PTC
75%). Asioli et al. [25], Koperek et al. [26], and
Sheu et al. [27] reported comparable results
although with percentages of even 0% in DSV
specimens. To conclude, DSV has different
pathological and molecular profiles when
compared to conventional PTC.
Tall Cell Variant
Main Features
The TCV was first described by Hawk and
Hazard in 1976 [28]; however, the descriptions
of PTC with tall cell morphology in the litera-
ture date back to 1948 [29]. Among PTCs they
found a group of tumors with ‘‘a distinctive
columnar cell shape with the height of the cell
being at least twice the breadth’’. The World
Health Organization (WHO) [1] defines TCV as
a tumor that is composed ‘‘of cells that are two
to three times as tall as they are wide, and that
show abundant eosinophilic (oncocytic-like)
cytoplasm. Because tall-cell areas are frequently
present in otherwise conventional papillary
carcinomas, tall cells must account for C 30%
of all tumor cells for the diagnosis of the tall-cell
variant’’. This definition varies from the 2004
WHO Classification which defines TCV as a
tumor ‘‘composed predominantly’’ of neoplastic
cells with a 3:1 height to with ratio. The per-
centage of tall cells needed to make a TCV
diagnosis varies between the studies: Ganly
et al. [30] recommend at least 30%, Beninato
et al. [31], and Oh et al. [32] suggested that
when the tumor is composed of more than 10%
tall cells, it is an aggressive variant. Some expert
histopathologists such as LiVolsi [33] recom-
mend that a focus of tall cells be mentioned in
the pathology report, regardless of the percent-
age. These findings should encourage the
managing clinician to monitor the patient
3116 Adv Ther (2020) 37:3112–3128
closely after treatment, given the greater
aggressiveness of these tumors.
Wang et al. [34] noticed that TCV is more
frequent in women, with a female to male ratio
of approximately 2.9:1. In 2017, Gunalp et al.
reported 3128 well-differentiated thyroid carci-
nomas, including 56 TCV, 66% of which
occurred in women. In their study, TCV repre-
sents approximately 1–19% of PTC, usually in
older patients and are often large in size at
diagnosis [35]. Kazaure et al. [11] reported that
the incidence of TCV had increased by 158%
over 20 years. The average age of patients with
TCV is usually higher than that of patients with
PTC, and ranges from 41 to 66 years [11, 34, 36].
TCV is associated with a higher recurrence rate
and shorter survival than classic PTC. This may
be because it occurs in older patients, presents
with larger tumor size, and more frequent
extrathyroidal involvement. Even when the
authors corrected for some factors like age,
gender, and tumor size, this variant still
remained more aggressive than classic PTC [37].
In contrast, Ganly et al. [30] observed in mul-
tivariate analysis that the presence of more than
five positive nodes and extranodal extension
were the only independent prognostic factors of
neck and distant recurrence-free survival raising
the issue of whether tall cell variant is more
aggressive than classic PTC when stratified by
stage. Russo et al. [38] found that TCV and
classic PTC had similar outcome when treated
Fig. 1 a Scanning view of thyroidectomy specimen
affected with DSV of PTC classically showing the lack
of mass-forming lesion. b Low power microscopic view
(4 9 10) of DSV showing numerous psammoma bodies
and tumor cells infiltrating throughout the thyroid
parenchyma associated with fibrosis and chronic lympho-
cytic thyroiditis. c Low power microscopic view (4 9 10)
of SV of PTC showing a trabecular and nested growth.
d High power microscopic view (40 9 10) of SV showing
diagnostic nuclear features of papillary thyroid carcinoma,
including nuclear enlargement, chromatin clearing, over-
lapping, irregular nuclear membranes and grooves in the
absence of diagnostic criteria for poorly differentiated
thyroid carcinoma. e High power microscopic view of a
solid variant of papillary thyroid carcinoma occurring in a
10-year-old Ukrainian boy exposed to the Chernobyl
disaster. The tumor is composed of solid/nests (arrow)
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similarly with total thyroidectomy and RAI. In a
recent meta-analysis, Vuong et al. [39] found
that even PTCs with only 10% tall cells were
associated with a poor clinical outcome. They
suggest that the presence of tall cells in a small
percentage, even only 10%, must be reported.
Bongers et al. [40] studied the proportion of tall
cells needed to influence prognosis in a series of
96 PTCs with focal tall cell change, 35 with the
TCV histology, and 104 control cases. Factors
associated with poor clinical prognosis were
significantly more common in those with focal
tall cell change and TCV. Five-year disease-free
survival was higher for the control group
(92.7%, CI 87.4–98.0) compared with focal tall
cell change (76.3%, CI 66.1–86.5) and the TCV
histology (62.2%, CI 43.2–81.2). When stratified
in groups consisting of tall cell proportions
(\10%, 10–19%, 20–29%, and C 30%), identi-
fication of at least 10% tall cell change was
associated with worse outcome (P = 0.002). In
contrast, Wong et al. [41] reported that only
tumors with greater than 50% of tall cell com-
ponent had a more aggressive behavior. Thus,
the proportion of tall cell component that is
clinically relevant is still a matter of debate. In
addition, it is important to highlight that there
is significant subjectivity and lack of agreement
in the identification and reporting of TCV of
PTC among pathologists [42]. Likewise, the
reported percent of a given tumor composed of
tall cells is a visual estimate contingent on tissue
sampling. On the basis of the above data, it is
still unclear whether stage for stage tall cell
variant is more aggressive than classic PTC.
Diagnosis
Histological Features
In addition to being defined by the presence of a
significant proportion of tall cells as described
above, tall cell variant PTC exhibits stretched
elongated follicles in histologic sections (Fig. 2a,
b). This finding also termed ‘‘tram-track
appearance’’ is quite characteristic of this vari-
ant and should prompt a search for tall cells
when detected at low magnification. Although
most TCVs PTC are not encapsulated, rarely one
can encounter an encapsulated tumor even a
non-invasive encapsulated TCV. Other histo-
logical diagnostic criteria of TCV include eosi-
nophilic cytoplasm, distinct cell borders, and
prominent/exaggerated nuclear features of PTC.
These features have not received enough
attention in the literature, and it is important to
recognize that the diagnosis TCV is not limited
to a specific height to width ratio and percent-
age criteria. Several studies have tried to define
the cytologic features that differentiate TCV
from classic PTC on FNA. TCV is characterized
by elongated tall cells with oncocytic cyto-
plasm, distinct cell borders, different intranu-
clear inclusions (compared with classic PTC),
prominent central nucleoli, multiple inclusions
within the same nucleus imparting a ‘‘soap
bubble appearance’’, and higher frequency of
cases with lymphocytic infiltration [43, 44].
Molecular Features
As with PTC, the role of the BRAFV600E mutation
in TCV has been investigated. It has been
observed that its prevalence in TCV is between
80% and 100%. Wong et al. [41] found that the
higher frequency of BRAF mutations was found
in cases with greater than 50% of tall cell com-
ponent, and that these cases frequently have a
pathogenic secondary mutation (usually in the
TERT promoter gene). RET/PTC rearrangements
have also been studied, with RET/PTC3 descri-
bed in 35.8% of TCV cases, compared with
17.2% in classic PTC [32, 45, 46]. Moreover, the
Cancer Genome Atlas (TCGA) reported that
cases of TCV cluster together at the mRNA level
and were characterized by miR-21 expression
[47]. These differences in the rate of driver
mutations could be due to differences in the
definition of TCV PTC.
Columnar Cell Variant
Main Features
The CCV of PTC is a rare subtype that accounts
for 0.15–0.2% of all PTCs [48]. It is known to have
a rapid growth rate, associated with local invasion
and early development of lymph node metastasis,
and has a high rate of recurrence [49]. This
aggressive variant may not respond to RAI ther-
apy [37]. CCVs are described in the WHO
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classification as ‘‘typically hypercellular neo-
plasms showing thin papillae or glandular-like
spaces lined by pseudostratified epithelium,
which can also be seen on FNA. The neoplastic
cells show occasional subnuclear vacuolization or
even clear cytoplasm’’ [1]. The mitotic activity is
elevated, with a Ki67 index of about a 20% or
higher. CCV lesions are positive for TTF1, thy-
roglobulin, cyclin D1, bcl-2, membranous local-
ization of b-catenin, and estrogen and
progesterone expression regardless of the gender
of the patient, and occasionally can be positive
for CDX2 (up to 55% of cases) [37, 50, 51]. CCVs
can be encapsulated or present as an infiltrating
mass. Often the most common finding is an
asymptomatic or enlarging neck mass [52]. Cho
et al. [53] in their study of six CCV cases (one
male and five female) reported a median age of
34 years (mean 41.7). Chen et al. [54] describe
nine cases (five male, four female) of CCV, with a
mean age of 57 years. Bongiovanni et al. pub-
lished 11 specimens of FNA cytology (from three
Fig. 2 a Medium magnification view (20 9 10) of a TCV
of PTC showing elongated follicles with parallel arrange-
ment (‘‘tram-track’’ appearance). b High magnification
view (60 9 10) of TCV exhibiting tumor cells that are
taller than wider (2:1 or 3:1 height to width ratio) with
moderate to abundant light eosinophilic cytoplasm,
distinct cell borders, and prominent nuclear features
diagnostic of PTC. c Low power microscopic view
(4 9 10) of CCV of PTC showing a highly cellular
neoplastic proliferation. d High magnification view
(40 9 10) of CCV exhibiting elongated tumor cells and
hyperchromatic nuclei and prominent nuclear stratifica-
tion, the cardinal feature of this variant. e Medium
magnification view (20 9 10) of an HV of PTC showing
complex papillary growth and micropapillary architecture.
f High magnification view (60 9 10) of tumor cells with
hobnail morphology characterized by pleomorphism, high
nuclear to cytoplasmic ratio, apically or eccentrically placed
nuclei, and surface bulging
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male and seven female patients, with a mean age
of 49.4 years).
Wang et al. [55] and Jiang et al. [56] have
both used the SEER database to demonstrate
that CCV is associated with higher rates of
extrathyroid extension, nodal and distant
metastases, and poorer overall survival in com-
parison with classic PTC. Average survival in the
study by Wang et al. was 44.06 ± 33.01 months
compared to an average survival of
48.89 ± 33.4 months for classic PTC
(p\ 0.001), and the rates of cancer-specific
mortality per 1000 person-years for CCV and
PTC were 16.85 (95% CI 13.11–21.65), and 2.51
(95% CI 2.32-2.72), respectively. In the study by
Jiang et al. [56], the 10-year overall survival was
89.02% (96.98% in classic PTC; p\ 0.0001).
However, in the seminal study by Wenig et al.
[52], the patients’ tumors were divided into
encapsulated with minimal invasion and widely
infiltrative. The encapsulated tumors occurred
mostly in young female patients while the
infiltrative ones in older patients with an almost
equal male to female ratio. The encapsulated
minimally invasive CCV behaved in a very
indolent fashion while the widely infiltrative
tumors had a very poor outcome. This impor-
tant study demonstrates that columnar cell
variant when encapsulated and confined to the
thyroid has an outcome similar to classic PTC.
Although as a group CCV is more aggressive
than classic PTC, it may not be true when these
carcinomas are compared according to their
invasive status. This has important implications
for risk stratification and therefore therapy.
Diagnosis
Histological Features
The CCV is histologically defined by the presence
of a significant amount of columnar cells dis-
playing pseudostratified nuclei (Fig. 2c, d). The
nuclear features of papillary carcinoma are not as
well developed as in classic PTC or TCV PTC. The
morphological appearance of CVV can mimic
adenocarcinomas of the gastrointestinal tract and
endometrium. There is no consensus as far as the
percentage of columnar cells required for that
diagnosis. Indeed, the proportion required
according to different authors ranges from 30% to
80% [52, 57]. According to Bongiovanni et al. [57]
there are several cytomorphologic features that
are common in all FNAs from CCV tumors: high
cellularity, papillae, medium or large cell size,
single cells, and pseudostratified nuclei (nuclear
crowding). There are other characteristics seen in
more than 50% of the cases: colloid, elongated
cells, dark or densely packed chromatin, absent or
mild nuclear atypia, inconspicuous nucleoli, and
the absence of intranuclear pseudoinclusions. On
the basis of these findings, the cytological features
that can be of diagnostic help are (1) the presence
of a hypercellular smear composed of papillary
structures and dispersed single cells lacking
necrosis; (2) the presence of cellular crowding and
pseudostratified nuclei with dark chromatin
without atypia, nucleoli, or mitosis; and (3)
scarce/absent nuclear pseudoinclusions and pre-
dominantly scarce/absent nuclear grooves. These
tumors show variable thyroglobulin expression,
but their constant expression of TTF1 is helpful in
diagnosing this variant [58]. TCV should be con-
sidered in the histological differential diagnosis.
In contrast to TCV, CCV tumor cells typically lack
light eosinophilic cytoplasm and delicate cell
borders. The absence of easily identifiable
intranuclear pseudo-inclusions and nuclear
grooves would also favor CCV [58]. It is important
to differentiate the encapsulated columnar cell
variant from the cribriform-morular variant of
PTC since the latter can be the first manifestation
of familial adenomatous polyposis. Columnar cell
variant usually lacks the squamous morules typi-
cal for the cribriform-morular variant and does
not have nuclear expression for beta-catenin [54].
Molecular Features
Chen et al. [54] demonstrated that 33% of their
cases of CCV had the BRAFV600E mutation, a
percentage somewhat similar to that expressed
by the classic PTC, which supports the idea that
the CCV are a variant of PTC.
Solid Variant
Main Features
SV is one of the rarest subtypes (3% of all PTC)
[59] and was described in 1985 by Carcangiu
3120 Adv Ther (2020) 37:3112–3128
et al. [60]. It was initially linked to young age,
RET/PTC3 fusions, and radiation exposure. After
the Chernobyl accident, 37% of the subsequent
PTC cases were SV [13]. However, SV has also
been described in patients who have not been
exposed to radiation [61]. Chang et al. [62]
reviewed 14 cases of SV, none of whom had
been exposed to radiation. The 12 women and 2
men had a mean age of 48.2 years. Guleria et al.
[63] reported nine cases with a mean age of
43.9 years, five male and four female.
SV is associated with a higher risk of metastasis
and a worse prognosis than classic PTC [64]. It is
common for PTCs to have areas of solid and/or
trabecular growth, which is more common for
tumors in the pediatric age group [1, 65]. How-
ever, the term ‘‘solid variant’’ should be used
when all or nearly all of the tumor has a solid,
trabecular, or nested (insular) appearance. The
most frequent differential diagnosis is follicular
carcinoma with a solid pattern [37] and poorly
differentiated thyroid carcinoma. One-third of
patients present with vascular invasion and
extrathyroidal extension [66]. Chang et al. believe
that the clinical characteristics of the SV are the
same as those of the classic PTC in terms of fre-
quency of lymph node metastases, distant
metastases, and recurrences [62]. In contrast,
Vuong et al. [67] found in their meta-analysis of
11 studies of 205 cases of SV that this is an
aggressive variant with higher risk of tumor
recurrence and mortality. Ohashi et al. [68] in
their study with 27 SV patients found that com-
pared with classic PTC, SV was associated with
larger tumor size, higher rates of lymphovascular
invasion, lymph node metastases, extracapsular
infiltration, higher recurrence rate, and shorter
disease-free survival.
Diagnosis
Histological Features
One of the problems in attempting to diagnose
SV is the lack of consensus as to what solid
proportion of the cancer is necessary for a
diagnosis of SV. Nikiforov and Gnepp [13] used
70%, whereas Carcangiu et al. [60] and Ohashi
et al. [69] require a 50% solid component pro-
portion. According to the latest WHO
classification of endocrine tumors, all or nearly
all of the tumor should be composed of a solid
growth pattern [1]. It is very important to dif-
ferentiate the solid variant from poorly differ-
entiated thyroid carcinoma since the latter
imparts a much poorer survival rate. Although
they share a solid growth pattern, the solid
variant exhibits nuclear features diagnostic of
PTC and lacks the high mitotic rate and tumor
necrosis found in poorly differentiated thyroid
carcinoma. Guleria et al. [63] state that ‘‘the
presence of solid fragments as the predominant
architecture and total lack of true papillae in a
cytology smear showing diffuse and well-de-
veloped nuclear features favor a diagnosis of
SV’’. Another characteristic is the lack of
necrosis and prominent mitotic activity [37]
(Fig. 1c–e).
Molecular Features
The RET/PTC3 rearrangement is usually
observed in this variant of PTC [65]. Trovisco
et al. [70] detected a novel BRAF mutation in a
case of SV, a triplet deletion in BRAF leading to
the replacement of a valine and a lysine by a
glutamate (BRAFV600E?K601).
Hobnail Variant
Main Features
HV is a rare variant of PTC described by Asioli
et al. [25] in 2010 as a moderately differentiated
PTC variant with aggressive behavior and sig-
nificant mortality. However, previous reports
from Japanese researchers indicated that PTC
with this morphology was associated with
increased risk of recurrence in thyroid cancer
[71, 72]. This variant is characterized by ‘‘hob-
nail’’ cells (i.e., apically located tumor nuclei
bulging from the surface of the epithelium),
micropapillary growth patterns, and a high
nuclear/cytoplasmic ratio. In order for a tumor
to be labeled as hobnail variant, the hobnail
cells should comprise at least 30% of the neo-
plastic cells according to the most recent WHO
classification of endocrine tumors [1]. Review-
ing 2534 PTC from 1955 to 2004 at the Mayo
Clinic, Asioli et al. found eight cases (six women
and two men), with a mean age of 57.6 years
Adv Ther (2020) 37:3112–3128 3121
and the most common initial symptom was a
neck mass and cervical lymphadenopathy [25].
In a 2013 paper [73], the same authors retro-
spectively analyzed 24 cases of HV (including
the eight cases previously described in 2010),
with a mean age of 57.3 years (18 women and 6
men). Vascular invasion was detected in 70.8%
of the cases and extrathyroidal extension in
58.3%. The overall survival at 5 and 10 years
was 69.1% and 64.1%, respectively. The authors
conclude that HV appears to be more aggressive
than classic PTC, regardless of the proportion of
hobnail/micropapillary features. In 2014, Lubitz
et al. [74] analyzed 12 cases of HV (average age
54.1 years, nine female and three male), fre-
quently finding extrathyroid extension (58.3%),
lymphovascular invasion (41.7%), and lymph
node metastasis (75%). Amacher et al. [75]
confirmed the more aggressive behavior of HV.
Observing hobnail features more commonly in
poorly differentiated thyroid carcinoma than in
classic PTC, they suggested it may be a sign of
higher-grade transformation. HV is associated
not only with more aggressive behavior but also
with RAI refractoriness, disease progression, and
a higher mortality rate compared to classic PTC
[76]. Morandi et al. [77] analyzed 18 HV and
only 33.3% of the cases were responsive to RAI
therapy.
Diagnosis
Histological Features
A ‘‘hobnail pattern’’ is the term for describing
cells with a high nuclear/cytoplasmic ratio and
apically placed, occasionally grooved nuclei
that produce a surface bulge, accounting for the
term ‘‘hobnail’’ or ‘‘matchstick’’. Hobnail cells
can vary in size and shape, from small lym-
phocytoid cells to larger cuboidal cells and even
tall/columnar cells (Fig. 2e, f). The hobnail pat-
tern is associated with the loss of cellular
polarity and the loss of cohesiveness and sug-
gests an epithelial-mesenchymal transition as a
possible mechanism of metastasis [25, 78]. HVs
are positive for thyroglobulin, TTF1, and
epithelial membrane antigen (EMA). Overex-
pression of p53 protein by immunohistochem-
istry has been reported in more than 25% of the
neoplastic cell nuclei in 77% of cases. b-catenin
and E-cadherin stains show patchy lateral and/
or basolateral membrane positivity. HV also
displays cytokeratin 7, cytokeratin 19, and
HBME-1 as well as a mean Ki67 index of about
10% [73, 78]. The latter finding is consistent
with the fact that HVs have often a high mitotic
rate. Indeed, the presence of at least 3 mitoses/
10 high power fields was found in 70% of cases
in one study [79]. Recently, Wong et al. [79]
have shown that classic PTCs can have cells
with hobnail morphology in a significant por-
tion of the tumor and still maintain a very
indolent course. However, these classic PTCs
with hobnail cells differ from the aggressive HVs
by the lack of other aggressive histologic fea-
tures such as high mitotic rate and extrathyroid
extension. One therefore could question whe-
ther the aggressive behavior of the HV is due to
its high mitotic rate or extensive invasion rather
than the presence of the typical hobnail cells.
Molecular Features
According to the first description by Asioli et al.
[25], BRAF mutations were detected in 57.1% of
cases. Lubitz et al. [74] found that the mean
percentage of BRAFV600E alleles was 25.3%. They
also found that 80% of the tumors were positive
for BRAFV600E while 20% harbored RET/PTC1
fusions.
Morandi et al. [77] investigated the molecu-
lar data of HV and found that BRAF and TP53
mutations were the most common genetic
alterations in primary HV (72.2% and 55.6%,
respectively), followed by hTERT (44.4%),
PIK3CA (27.8%), CTNNB1 (16.7%), EGFR
(11.1%), AKT1 (5.5%), and NOTCH1 (5.5%).
The mutational pattern remains unaltered in
the primary tumor and in metastasis. Univariate
Cox regression analyses indicated a significantly
increased mortality risk in patients with BRAF
mutation. Further increase in mortality was
seen in BRAF mutation associated with TP53
and/or PIK3CA mutations.
TREATMENT
According to the ATA recommendations [3],
treatment of all of these histological variants is
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basically the same: Lobectomy for small unifo-
cal intrathyroidal tumors and total thyroidec-
tomy, with therapeutic neck dissection if nodes
are involved or prophylactic central compart-
ment node dissection for T3 and T4 tumors.
Following the total thyroidectomy, the need for
RAI therapy should be considered. Wang et al.
[55] suggested that because of the poorer prog-
nosis of CCV, radical approaches should be
considered. It is important to identify the
indolent cases as they have a better outcome
with a low incidence of recurrences or metas-
tasis [52, 53, 56]. For TCV one must take into
account that approximately 20% are refractory
to RAI. Gunalp et al. [35] found that TCV his-
tology implies a higher incidence of extrathy-
roidal and lymphovascular invasion, and
distant metastasis. These factors are responsible
for the higher recurrence rates and worse prog-
nosis of TCV compared with classic PTC. They
also recommend aggressive treatment especially
in early stages of the disease. As aggressive
recurrent thyroid tumors are frequently non-
RAI-avid and [18F]fluorodeoxyglucose (FDG)-
positron emission tomography (PET)-positive,
Rivera et al. [80] examined these carcinomas
microscopically. They found that 20% of the
cases were TCV with extensive extrathyroidal
extension into adjacent fibroadipose tissue and/
or skeletal muscle. Since most pathologists
nowadays are familiar with TCV PTC features
and sample generously the thyroid gland, it is
not uncommon to find small even subcen-
timeter TCV PTC confined to the thyroid
without vascular invasion. Because we do not
know if stage for stage TCV PTC is more
aggressive than classic PTC, aggressive treat-
ment of such incidental small TCV PTC should
be questioned in our opinion and treatment
decisions made in a multidisciplinary fashion.
In addition it is not clear how to treat patients
with PTC showing a tall cell component that
does not reach the ‘‘official’’ diagnostic per-
centage cutoff. In relation to CCV, it is impor-
tant to identify the indolent encapsulated cases
as they have a better outcome with a low inci-
dence of recurrences or metastasis [52, 53, 56].
With respect to SV, some authors suggest that
treatment and follow-up should be strict since
they have a greater rate of vascular invasion and
recurrence than classic PTC [67]. Early diagnosis
and close surveillance are essential in the man-
agement of patients with HV according to Asioli
et al. [25]. In the future these tumors may be
treated by targeting different molecular path-
ways [78].
One aspect that must be taken into account
is that DSV, which is more prevalent in children
and young patients, particularly tends to be
iodine-avid and even patients with distant
metastases have a good prognosis [81, 82]. On
the contrary, the other variants, which affect
mostly older patients, with locally invasive or
locally recurrent disease, are RAI refractory and
have a poor prognosis.
Reviewing the literature and the biological
behavior of all of the variants of PTC mentioned
above, it becomes evident that the ones which are
aggressive and have a poorer outcome are tumors
which are higher staged, have gross extrathyroid
extension, or those who present with nodal or
distant metastases. In general, the prognosis
remains excellent and similar to PTC, for small
(T1–2) tumors, which are intrathyroidal at pre-
sentation. Thus, the treatment decision is based
on the extent of tumor at presentation rather
than the histological variant of PTC.
DISCUSSION
Classic PTC is usually an indolent disease with
an associated 10-year survival of over 95% [2].
This manuscript describes the variants of PTC
with an aggressive behavior, placing them on
the spectrum between a low-grade PTC and
poorly differentiated/anaplastic thyroid carci-
noma. They appear to have higher rates of
metastases, recurrence, resistance to RAI ther-
apy, and compromised survival [18]. However,
such aggressive behavior is usually associated
with larger tumors presenting with extrathyroid
extension or nodal or distant metastases. The
rarity of these tumors and the poor under-
standing of their biology may lead to inade-
quate treatment. For this reason, we conducted
this review with the purpose of updating the
thyroid cancer clinician on the histological
characteristics of the aggressive variants of PTC
and the treatment implications for these
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patients. An early and correct diagnosis can lead
to appropriate treatment and improved prog-
nosis for these patients.
Unfortunately, the diagnosis can be con-
firmed with an FNA in very rare cases; however,
those cytology reports show be interpreted with
caution as an FNA specimen might not be rep-
resentative of the entire lesion and some vari-
ants need to reach defined tumor percentage
thresholds. In almost all instances the diagnosis
of aggressive variants of PTC is diagnosed after
surgery. Therefore, surgical pathologists should
be cognizant of the effect of these variants in
the risk stratification of patients with PTC.
There is no doubt that each of these aggres-
sive variants of PTC has worse outcome than
classic PTC as a whole (e.g., all TCV cases vs. all
patients with classic PTC). The important
question is the independent prognostic value of
these variants when stratified by stage or other
aggressive histologic features such as mitotic
rate and degree of invasion. This question has
been answered for the rarest aggressive variant
which is the CCV. The study by Wenig et al.
[52] clearly shows that the encapsulated form of
CCV is an indolent disease while the widely
infiltrative CCV is very aggressive. So, it is
encapsulation rather than the columnar cells
(the latter being the defining feature of CCV)
that drives outcome in CCV PTC. Unfortu-
nately, we do not have a definitive answer for
the other aggressive variant especially the most
common one which is TCV PTC. However, a
recent study by Limberg et al. [83] analyzed data
from the National Cancer Database and their
findings showed that in the absence of invasive
features, TCV, CCV, and DSV have similar
overall survival to that of classic PTC; and some
authors have shown that the presence of tall
cells is not an independent prognostic feature
[30].
Given this uncertainty as to the independent
prognostic value of these aggressive variants of
PTC, it is important to rely on established
prognostic features (such as large size, gross
extrathyroid extension, extensive vascular
invasion) when deciding on the extent of sur-
gery or the need for adjuvant therapy. For
example, an 8-mm TCV PTC confined to the
thyroid may not need more than a simple
lobectomy while TCV PTC with gross extrathy-
roid extension in the trachea will need total
thyroidectomy with or without tracheal resec-
tion depending on the extent of the tumor with
RAI therapy. The fundamental surgical principle
of ‘‘gross total excision’’, with an R0 resection
when feasible must remain the gold standard
for planning surgery for thyroid cancer. On the
other hand, with the identification of new
molecular targets and development of new
therapeutic agents, these tumors would be
excellent targets to explore the efficacy of new
systemic therapies and improvement in out-
comes through clinical trials.
CONCLUSIONS
The correct diagnosis of the most aggressive
variants of PTC can represent a diagnostic
challenge even for expert histopathologists.
Each aggressive variant imparts a worse out-
come than classic PTC. At the present time, we
do not know the independent prognostic value
of the morphology of aggressive PTC variants by
itself. In view of this uncertainty, the extent of
the surgical treatment and adjuvant therapy
required is an individualized decision made by
experienced clinicians guided by the extent of
tumor at initial presentation. Future well-con-
trolled outcome studies are needed to assess the
independent prognostic value of these variants.
Novel advances at the molecular level may open
the way for future targeted therapies that may
help improve the survival of these patients.
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